Pharma patent litigation is often described as a battle of legal teams and courtroom strategy. But the real cost is rarely the line item everyone can see.
It’s the opportunity cost. The operational drag. The delayed launches. The regulatory uncertainty…

Australia’s Drug Patent Clock: The Real Timeline Behind “Protection” (and Why It Rarely Matches the Headlines)
If you’ve ever heard that a drug is “protected until 2032” (or “won’t face generic competition until 2028”), you’ve probably been handed a si…

Pharma doesn’t always need a brand-new drug to extend its profits.
Sometimes it just needs a new version—and a legal pathway that lets it re-enter the patent landscape without starting from scratch.
That’s the core idea behind the “reformulation playbo…

Drug spend is not a mystery problem—it’s a timing problem.
If your organization is still negotiating drug prices without a clear view of when exclusivity ends, you’re not managing cost—you’re guessing. And in today’s market, guessing can be the diffe…

The “Drug Patent Cliff” Isn’t a Finance Problem—It’s a Procurement Problem.
If you’re a procurement leader, you’ve probably felt it: the sudden scramble when a key brand’s exclusivity ends, the frantic vendor calls, the “can we switch?” emails, the int…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical trials are supposed to be about evidence—patient outcomes, endpoints, safety signals, and regulatory clarity. But there’s a quieter risk growing …

The “Hard 20-Year Limit” in New Zealand Isn’t Just a Legal Detail—it’s the Clock That Decides Who Wins.
In drug development, timelines are everything. But in New Zealand, one particular timeline—an unusually rigid “hard 20-year limit”—quietly shapes al…

Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…

Pharma has a patent problem—and a tax problem.
For years, the industry has treated IP strategy like a pure play offense: file early, extend late, defend aggressively, monetize relentlessly. But the modern reality is that the “value” of a patent isn’t j…

The 180-Day Clock Is Not a Deadline—It’s a Battlefield.
Generic drug launches live and die by timing, but few timelines are as consequential—or as misunderstood—as the 180-day exclusivity period under the Hatch-Waxman framework. In theory, it’s a cle…